In Vitro Studies to Assess Biocompatibility of Peritoneal Dialysis Solutions: Strengths and Limitations

Van Bronswijk H. , Verbrugh H.A. , Bos H.J. Cytotoxic effects of commercial continuous ambulatory peritoneal dialysis (CAPD) fluids and of bacterial exoproducts on human mesothelial cells in vitro. Perit Dial Int 1989; 9: 197–202.

Kristensen S.R. , Pedersen F.B. Cytotoxicity testing of two CAPD dialysis fluids in a model system of quiescent fibroblasts. Nephrol Dial Transplant 1993; 8: 163–7.

Jörres A. , Gahl G.M. Effect of peritoneal dialysis fluids on leukocyte function. Perit Dial Int 1994; 14(Suppl 3): S29–S32.

Ing B.L. , Gupta D.K. , Nawab Z.M. Suppression of neutrophil superoxide production by conventional peritoneal dialysis solutions. Int J ArtifOrgans 1988; 11: 351–4.

Liberek T. , Topley N. , Jörres A. Peritoneal dialysis fluid inhibition of phagocyte function: Effects of osmolality and glucose concentration. J Am Soc Nephrol 1993; 3: 1508–15.

Liberek T. , Topley N. , Jörres A. Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH. Nephron 1993; 65: 260–5.

Wieslander A.P. , Nordin M.K. , Martinson E. Heat sterilized PD fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes. Clin Nephrol 1993; 39: 343–8.

Duwe A.K. , Vas S.I. , Weatherhead J.W. Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis and bactericidal activity in vitro. Infect Immun 1981; 33: 130–5.

Dobbie J.W. , Lloyd J.K. , Gall C.A. Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin Inc., 1990; 6: 3–12.

Heimburger O. , Waniewski J. , Werynski A. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38: 495–506.

Dobbie J.W. , Pavlina T. , Lloyd J.K. In vitro systems for testing effect of dialysate composition on mesothelium. Perit Dial Int 1990; 10(Suppl 1): S51.

Breborowicz A. , Karon J. , Korybalska K. Properties of mesothelial cells exposed to glucose or amino acid based dialysate effluents. Perit Dial Int 1995; 15(Suppl 1): S76.

Gotloib L. , Wajsbrot V. , Shostack A. Experimental approach to peritoneal morphology. PeritDialInt 1994; 14(Suppl 3): S6–S11.

Chamberlin M.E. , Strange K. Anisoosmotic cell volume regulation: A comparative view. Am J Physiol 1989; 257: C159–C173.

Gallimore B. , Gagnon R.F. , Stevenson M.M. Cytotoxicity of commercial peritoneal dialysis solutions towards peritoneal cells of chronically uremic mice. Nephron 1986; 43: 283–9.

Jörres A. , Jörres D. , Topley N. Leukotriene release from peripheral and peritoneal leukocytes following exposure to peritoneal dialysis solutions. Nephrol Dial Transplant 1991; 6: 495–501.

Topley N. , Mackenzie R. , Petersen M.M. In vitro testing of a potentially biocompatible continuous ambulatory peritoneal dialysis fluid. Nephrol Dial Transplant 1991; 6: 574–81.

Breborowicz A. , Martis L. , Oreopoulos D.G. Changes in biocompatibility of dialysis fluid during its dwell in the peritoneal cavity. Perit Dial Int 1995; 15: 152–70.

Haussinger D. , Lang F. , Gerok W. Regulation of cell function by the cellular hydration state. Am J Physiol 1994; 267: E343–E355.

Witowski J. , Topley N. , Jörres A. Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 1994; 46: 282–93.

Breborowicz A. , Rodela H. , Martis L. , Oreopoulos D.G. Intracellular glutathione in human peritoneal mesothelial cells exposedin vitro to dialysis fluid. (submitted)

De Fijter C.W.H. , Verbrugh H.A. , Peters E.D.J. Invivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD. Clin Nephrol 1993; 39: 75–80.

Jörres A. , Topley N. , Steenweg L. Inhibition of cytokine synthesis by peritoneal dialysate persists throughout the CAPD cycle. Am J Nephrol 1992; 12: 80–5.

Haag Weber M. , Horl W.H. Impact of continuous ambulatory peritoneal dialysis solutions and clearance of macromolecules on polymorphonuclear neutrophils. Perit Dial Int 1994; 14(Suppl 3): S33–S38.

Steinhauer H.B. , Brugger U. , Atmanspacher R. Effect of CAPD dialysate on the release of eicosanoids and cytokines from human peritoneal macrophages. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin Inc., 1992: 47–52.

Daniels I. , Lindsay M. , Porter C. Effect of peritoneal dialysis effluent on superoxide anion production by polymorphonuclear neutrophils. Nephron 1993; 64: 382–7.

Selgas R. , Lopez-Rias A. , Alvaro F. Insulin influence (used as additive to dialysate) on the mitogenicinduced effect of the peritoneal effluent in CAPD patients. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin Inc., 1989: 161–4.

Breborowicz A. , Oreopoulos D.G. Physiological approaches to increase biocompatibility of peritoneal dialysis. Perit Dial Int 1995; 15(Suppl 7): S76–86.